RPG Life Sciences buys Raghava API unit for up to Rs 135 crore
RPG Life Sciences acquired Raghava Life Sciences’ active pharmaceutical ingredients and intermediates business for up to Rs 135 crore, its second acquisition in just over a month.
RPG Life Sciences has acquired the active pharmaceutical ingredients and intermediates business of Raghava Life Sciences for up to Rs 135 crore, marking its second acquisition in just over a month as it looks to build scale in the fast-growing API manufacturing market. The transaction will be executed through a slump sale.